F

Faes Farma SA
MAD:FAE

Watchlist Manager
Faes Farma SA
MAD:FAE
Watchlist
Price: 5.38 EUR 0.37% Market Closed
Market Cap: 1.7B EUR
Section:
 

Relative Value

The Relative Value of one FAE stock under the Base Case scenario is hidden EUR. Compared to the current market price of 5.38 EUR, Faes Farma SA is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

FAE Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

2.9
P/S
P/S
Price to Sales
2.9
vs History
0
vs Industry
48
Median 3Y
2.4
Median 5Y
2.5
Industry
2.6
Forward
2.9
More Details
15.9
P/E
P/E
Price to Earnings
15.9
vs History
0
vs Industry
37
Median 3Y
11.4
Median 5Y
12.2
Industry
21.4
Forward
21.8
More Details
16.6
P/OCF
P/OCF
Price to OCF
16.6
vs History
7
vs Industry
37
Median 3Y
10.4
Median 5Y
11
Industry
16.4
More Details
11
P/FCFE
P/FCFE
Price to FCFE
11
vs History
68
vs Industry
19
Median 3Y
10.6
Median 5Y
20.4
Industry
22.8
More Details
2.3
P/B
P/B
Price to Book Value
2.3
vs History
0
vs Industry
46
Median 3Y
1.7
Median 5Y
1.8
Industry
2.2
More Details
2.9
EV/S
EV/S
Enterprise Value to Sales
2.9
vs History
0
vs Industry
47
Median 3Y
2.2
Median 5Y
2.3
Industry
2.9
Forward
2.9
More Details
4.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
4.5
vs History
0
vs Industry
56
Median 3Y
3.4
Median 5Y
3.6
Industry
5.5
More Details
13.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
13.5
vs History
0
vs Industry
37
Median 3Y
8.3
Median 5Y
8.4
Industry
13
Forward
13.5
More Details
16.4
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
16.4
vs History
0
vs Industry
38
Median 3Y
9.8
Median 5Y
10
Industry
16.5
Forward
18
More Details
16.5
EV/OCF
EV/OCF
Enterprise Value to OCF
16.5
vs History
0
vs Industry
38
Median 3Y
10
Median 5Y
10.7
Industry
15.6
More Details
23.1
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
23.1
vs History
39
vs Industry
20
Median 3Y
18.5
Median 5Y
21.1
Industry
18.7
More Details
2.1
EV/IC
EV/IC
Enterprise Value to IC
2.1
vs History
4
vs Industry
43
Median 3Y
1.6
Median 5Y
1.7
Industry
1.9
More Details

Multiples Across Competitors

FAE Competitors Multiples
Faes Farma SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
ES
Faes Farma SA
MAD:FAE
1.7B EUR 2.9 15.9 13.5 16.4
US
Eli Lilly and Co
NYSE:LLY
1.1T USD 17.7 57.3 38.6 41.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
500.7B USD 5.4 19.9 16.3 21.1
CH
Roche Holding AG
SIX:ROG
269.6B CHF 4.4 28.6 12.2 14.2
UK
AstraZeneca PLC
LSE:AZN
221.5B GBP 5.1 31.6 108.8 159.3
CH
Novartis AG
SIX:NOVN
219.5B CHF 4.9 19.1 12.1 15.6
US
Merck & Co Inc
NYSE:MRK
277.7B USD 4.3 14.5 10.3 12.2
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.2 15.8 11 12.8
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
144.7B USD 2.3 14.6 7.5 10.2
P/E Multiple
Earnings Growth PEG
ES
F
Faes Farma SA
MAD:FAE
Average P/E: 24.2
15.9
2%
8
US
Eli Lilly and Co
NYSE:LLY
57.3
54%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.6
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.6
37%
0.9
CH
Novartis AG
SIX:NOVN
19.1
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.5
15%
1
DK
Novo Nordisk A/S
CSE:NOVO B
15.8
3%
5.3
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
ES
F
Faes Farma SA
MAD:FAE
Average EV/EBITDA: 401.4
13.5
12%
1.1
US
Eli Lilly and Co
NYSE:LLY
38.6
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.3
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.2
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.8
10%
10.9
CH
Novartis AG
SIX:NOVN
12.1
6%
2
US
Merck & Co Inc
NYSE:MRK
10.3
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11
1%
11
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
ES
F
Faes Farma SA
MAD:FAE
Average EV/EBIT: 1 714.1
16.4
11%
1.5
US
Eli Lilly and Co
NYSE:LLY
41.4
36%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.1
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.2
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.3
23%
6.9
CH
Novartis AG
SIX:NOVN
15.6
12%
1.3
US
Merck & Co Inc
NYSE:MRK
12.2
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.8
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5

See Also

Summary
FAE intrinsic value, competitors valuation, and company profile.
DCF Valuation
FAE stock valuation using Discount Cash Flow valuation method.
Relative Valuation
FAE stock valuation using valuation multiples.
Wall Street Estimates
FAE price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
FAE stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 308,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.